As sDPP4 is an adipokine upregulated in obesity and T2DM that triggers IR and metabolic complications (4, 5), it might be speculated that the beneficial effects of DPP4 inhibitors would be higher in those early phases of the metabolic disorders previous to the development of established cardiovascular disease. Here, DPP4 is linked to obesity due to melanocortin 4 receptor deficiency.